These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20203496)

  • 21. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.
    Mannon PJ; Fuss IJ; Dill S; Friend J; Groden C; Hornung R; Yang Z; Yi C; Quezado M; Brown M; Strober W
    Gastroenterology; 2006 Sep; 131(3):748-56. PubMed ID: 16952544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis as a therapeutic tool in IBD?
    Lügering A; Lebiedz P; Koch S; Kucharzik T
    Ann N Y Acad Sci; 2006 Aug; 1072():62-77. PubMed ID: 17057191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signaling for inflammation and repair in inflammatory bowel disease.
    Neuman MG
    Rom J Gastroenterol; 2004 Dec; 13(4):309-16. PubMed ID: 15624029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
    Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
    Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innate immune signalling at intestinal mucosal surfaces: a fine line between host protection and destruction.
    Cario E
    Curr Opin Gastroenterol; 2008 Nov; 24(6):725-32. PubMed ID: 19122523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.
    Dignass AU; Baumgart DC; Sturm A
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innate immunity in inflammatory bowel disease: state of the art.
    Hisamatsu T; Ogata H; Hibi T
    Curr Opin Gastroenterol; 2008 Jul; 24(4):448-54. PubMed ID: 18622158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4 T-cell differentiation and inflammatory bowel disease.
    Zenewicz LA; Antov A; Flavell RA
    Trends Mol Med; 2009 May; 15(5):199-207. PubMed ID: 19362058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease.
    Shanahan F
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G417-21. PubMed ID: 15701620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response.
    Murray PJ
    Curr Opin Pharmacol; 2006 Aug; 6(4):379-86. PubMed ID: 16713356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies.
    Creed TJ; Probert CS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):111-22. PubMed ID: 17229236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary lactoferrin does not prevent dextran sulfate sodium induced murine intestinal lymphocyte death.
    Spagnuolo PA; Hoffman-Goetz L
    Exp Biol Med (Maywood); 2008 Sep; 233(9):1099-108. PubMed ID: 18535168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
    Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
    Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological therapies of inflammatory bowel disease.
    van Deventer SJ
    Acta Gastroenterol Belg; 2001; 64(2):177-81. PubMed ID: 11475130
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of magnetic field for the reduction of inflammation: a review of the history and therapeutic results.
    Ross CL; Harrison BS
    Altern Ther Health Med; 2013; 19(2):47-54. PubMed ID: 23594452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical aspects of inflammation.
    Kulinsky VI
    Biochemistry (Mosc); 2007 Jun; 72(6):595-607. PubMed ID: 17630904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evolution of clinical trial design investigating biological therapies in patients with inflammatory bowel disease - implications for clinical practice].
    Bettenworth D
    Z Gastroenterol; 2017 Mar; 55(3):304-306. PubMed ID: 27919109
    [No Abstract]   [Full Text] [Related]  

  • 40. Serological Status of Inflammatory Bowel Disease Patients Before Starting Biological Therapy - Data From a Tertiary Centre of the Best Vaccined Country.
    Szántó KJ; Rutka M; Pigniczki D; Farkas K; Burián K; Terhes G; Molnár T
    Inflamm Bowel Dis; 2020 Mar; 26(4):e28. PubMed ID: 31974586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.